Search This Blog

Wednesday, March 31, 2021

Caregiver and physician on financial implications of dementia

 In his recent First Opinion, “The long, exhausting reach of dementia care,” Jason Karlawish, a geriatric physician and co-director of the Penn Memory Center, wrote about how the coronavirus pandemic has led more Americans to realize how all-consuming life as a full-time caretaker can be. As many spouses and adult children of Alzheimer’s patients have long known, it’s often an isolating, arduous, and expensive experience.

To learn more about the implications of dementia, both individual and systemic, STAT’s Patrick Skerrett spoke with Karlawish and Richard Bartholomew, who was the caregiver for his late wife while she was living with Alzheimer’s.  

This conversation has been lightly edited and condensed for clarity.

Jason, you’ve written that financial issues are often an early sign of Alzheimer’s. How does that work?  

Jason: I like to say that the banking and financial services industries are on the front line of America’s effort to detect and diagnose disabling cognitive impairments.  These are diseases of what’s called “higher cortical function,” namely our brain’s ability to think, decide, take in new information, and use social cognition appropriately. The hardest tasks are the ones that are affected earliest. This isn’t just anecdote, but multiple well-done studies following hundreds of people for years have shown this. So even before the stages of mild cognitive impairment, you will see folks having trouble doing financial tasks, making mistakes, being victims of fraud and exploitation. Once upon a time when everything was on paper, it was sort of hidden in plain sight. But now that everything’s electronic, financial firms are seeing this.

But nobody’s really monitoring that except the individual and her or his family?  

Jason: Yes and no. Some firms have been proactive and make efforts when a suspicious transaction occurs. Some firms have stepped in and offered the ability for trusted caregivers and contacts to monitor accounts without having access to the actual funds. There are even companies that have developed software so they can monitor someone’s account. But I think the point you’re getting at is: those things are not normative in the industry. That has not become a standard practice. That’s something that’s exceptional, which I think needs to change. I just think it’s unacceptable. It’s like cars without seatbelts.


In the United States, it’s up to families to provide care for loved ones with Alzheimer’s and other forms of dementia and pay for it. What kind of services are you able to recommend to patients and their caregivers?

Richard: One thing I didn’t understand as a caregiver, that Dr. Karlawish explained to me, was the origin of Medicare-based hospice and how difficult it is for doctors who are working with Alzheimer’s patients to know when they are really in the terminal stages, and can justify hospice care.  

Jason: That’s right. The hospice benefit was designed for cancer. With persons living with dementia, arriving at a prognostic estimate that they have a prognosis of six month or less (the requirement for hospice care) is very difficult. And I think it’s one of several barriers to accessing the services and supports of hospice. Quite frankly, I think what hospice provided your wife she needed for a while, even if we weren’t thinking she was dying.

The other kind of care I often recommend is an adult day activity program, also called adult day care. And Richard, you witnessed the paucity of the programs and the quality of them. And it’s not because the programs are bad. It’s because they’re so profoundly under-resourced. And so I remember you would come back and say, ‘I found a great one, but it’s in a basement somewhere with no windows.’ 

In principle, adult-day programs should work. But they have struggled and many sadly shut down because of Covid. So they live on the economic margins. America doesn’t have an organized social insurance program, so they struggle to make ends meet. It’s an indictment of our health care system.

The Centers for Disease Control and Prevention and others project that the number of people with Alzheimer’s and other forms of dementia is going to double in the next three to four decades. That means the number of family caregivers will also double. Richard, having been a long term and loving family caregiver, do you have any advice to offer people who someday will be doing what you’ve done? 

Richard: I think we were extremely lucky. I did take a caregiver course at the Memory Center, I think before we started seeing Dr. Karlawish. So I heard in this small group of probably 10 people — all of us were caregivers — stories about what it’s like for other people with spouses with some form of dementia. And I was very lucky in that respect.

Jason: Yes, it’s the support that we were able to give you, Richard, included that caregiving class, our social work team, and others. And what’s interesting is that those supports that we provide have been made possible by a generous philanthropic gift from the Kaplan Family Foundation. If we had relied on billing through usual routes, of clinical billing through Medicare, we couldn’t pay the salaries of the people who run these programs. We couldn’t have provided that class. 

And it’s only going to get worse because will be more people who need care and fewer people who can care for them. We’re going to face the Alzheimer’s crisis. We already are in it, I would argue. And much of it is a crisis of our inability to organize a health care system to take care of people who are disabled from diseases like Alzheimer’s.

We should expect and hope for better treatments that slow the disease. But without treatments that slow each and every cause of the disease, we’re going to have to learn how to live with some degree of cognitive disability that needs care. So we really need to start a national conversation about how we’re going to organize a system of care for people like Richard Bartholomew and his wife, Julia Converse. 

And I am cautiously optimistic that the events of the last 12 months have woken us to caregiving, have made us realize how essential this very human activity is. And maybe, going forward, policymakers will listen.

https://www.statnews.com/2021/03/31/caregiver-and-physician-discuss-caregiving-dementia/

CDC: Age-adjusted death rate up 15.9% in 2020; COVID 3rd Leading Cause

 The CDC released the Provisional Mortality Data — United States, 2020 today:

During January–December 2020, the estimated 2020 age-adjusted death rate increased for the first time since 2017, with an increase of 15.9% compared with 2019, from 715.2 to 828.7 deaths per 100,000 population. COVID-19 was the underlying or a contributing cause of 377,883 deaths (91.5 deaths per 100,000). COVID-19 death rates were highest among males, older adults, and AI/AN and Hispanic persons. The highest numbers of overall deaths and COVID-19 deaths occurred during April and December. COVID-19 was the third leading underlying cause of death in 2020, replacing suicide as one of the top 10 leading causes of death

https://www.calculatedriskblog.com/2021/03/cdc-age-adjusted-death-rate-increased.html 

How Many Seniors Have Osteoporosis?

 About one in five American women 50 and older have osteoporosis, National Health and Nutrition Examination Survey (NHANES) data showed.

In cross-sectional survey data from 2017-2018, 19.6% of this demographic had osteoporosis at the femoral neck, lumbar spine, or both, reported Neda Sarafrazi, PhD, of the National Center for Health Statistics (NCHS) in Hyattsville, Maryland, and colleagues in an NCHS Data Brief.

The age-adjusted prevalence of osteoporosis in men was far lower, afflicting only about 4.4% of men 50 and older.

All in all, osteoporosis was present in 12.6% of all American adults 50 and older, which was defined as a bone mineral density (BMD) value at least 2.5 standard deviations below young-adult average at the femoral neck or lumbar spine.

In NHANES, lumbar spine and femoral neck BMD were measured by dual energy X-ray absorptiometry on Hologic Discovery Model A Densitometers.

Not surprisingly, osteoporosis was far more common among older adults, affecting 17.7% of all men and women 65 and older, versus 8.4% of those ages 50-64.

Rates stood at 27% for women ages 65 and older and 13.1% of women at ages 50-64.

In men, prevalence values were 5.7% in those 65 and older and 3.3% in the 50-64 group.

Osteoporosis became slightly more common over the years, Sarafrazi's group found. In 2007-2008, osteoporosis was seen in 9.4% of Americans 50 and older. The biggest uptick occurred in women, increasing nearly 5 percentage points from the earlier period. Rates remained steady throughout the years for men.

"Monitoring the prevalence of osteoporosis and low bone mass may inform public health programs that focus on reducing or preventing osteoporosis and its consequences," Sarafrazi's group noted. "Healthy People 2020 has a goal of 5.3% or less for the prevalence of osteoporosis at the femur neck for adults aged 50 and over."

"In the United States, the prevalence of osteoporosis among adults aged 50 and over at the femur neck only was 6.3% and has not met the 2020 goal," they underscored.

The data also showed an epidemic of low bone mass -- a precursor of osteoporosis, defined as BMD of 1 to 2.5 standard deviations below the young-adult average.

Among all adults ages 50 and older, 43.1% had low bone mass at the femoral neck, lumbar spine, or both. Prevalence was 51.5% among women and 33.5% among men.

The overall rate hit 47.5% in those 65 and older. But older age was less of a factor for women, with almost no difference between the 50-64 and 65-plus age groups.

For both sexes, prevalence rates of low bone mass held steady during the decade between 2007-2008 and 2017-2018.


Primary Source

Illumina upped to Buy from Hold by Canaccord

 Target $445

https://finviz.com/quote.ashx?t=ILMN

J&J vax partner Emergent still lacks FDA's manufacturing green light

 The U.S. manufacturing partner turning out drug substance for Johnson & Johnson's single-dose COVID-19 vaccine is still waiting on an FDA green light, potentially putting a squeeze on J&J's supply pipeline.

The FDA is weighing an emergency nod for Emergent BioSolutions, tapped in July 2020 to provide large-scale drug substance manufacturing for J&J's shot, Politico reported, citing two people familiar with the company's emergency use authorization process.

The regulator could clear Emergent "very soon," one source said.

While Emergent has been shipping millions of doses to J&J's U.S. fill-finish partner Catalent, which itself snared authorization last week, those shots can't be used until Emergent earns its emergency nod. In the meantime, J&J has been flying in drug substance from the Netherlands, one source told Politico.

Emergent couldn't comment on the specifics of its production work, but a spokesperson said via email that the company's "Baltimore Bayview facility continues to support COVID-19 vaccine production on a large scale and is capable of producing drug substance to support more than 1 billion doses annually."

The manufacturer is on track to meet its orders from J&J and AstraZeneca, he added. 


The issue stems from the fact that J&J didn't include its manufacturing partners in its original emergency use application, Politico said. In recent weeks, Biden administration officials have raised flags about whether the company can meet its delivery goal.

But J&J says it's on track to provide a promised 20 million doses by the end of the month and 100 million by June, a company spokesperson said via email.

"To meet our global commitments, we have established a global vaccine supply network where multiple manufacturing sites are involved in the production of the vaccine across different facilities, sometimes in different countries and continents, before the vaccine can be distributed globally once authorized for use by health authorities," the spokesperson said.

The company expects to deliver more than 1 billion COVID-19 vaccine doses this year and is in good shape to meet its 2021 supply pledges, he added. As of Monday, around 5 million J&J vaccines had been deployed in the U.S., according to the Centers for Disease Control and Prevention.

The news of Emergent's impending emergency nod follows last week's authorization of Catalent's Bloomington, Indiana, plant, where the CDMO in April agreed to reserve space for fill-finish work. The move could allow Catalent to release millions of vials that have already been packaged and inspected, Bloomberg reported last week, citing anonymous sources.


Catalent will soon play an upsized role in J&J's European manufacturing operation, too, thanks to a second high-speed vial-filling line the CDMO is adding at its fill-finish plant in Anagni, Italy. The upgrade, pegged for completion in the fourth quarter, should double capacity at the facility, Catalent said.

J&J aims to deliver 200 million doses to the EU this year.

As J&J's shot starts rolling out around the world, the company continues to strike supply deals. Monday, the drugmaker said it would provide the African Union with up to 400 million doses through 2022. Deliveries from an initial 220 million-dose tranche are expected to begin in the third quarter, with the remaining shots to roll out through next year.

https://www.fiercepharma.com/manufacturing/j-j-covid-19-vaccine-partner-emergent-could-soon-win-fda-manufacturing-nod-reports

FibroGen upped to Buy from Neutral by B of A

 Target $47

https://finviz.com/quote.ashx?t=FGEN

Why ProPhase Labs Shares Jumped 32%

 Shares of ProPhase Labs Inc 

PRPH, a consumer healthcare and diagnostics company, jumped 32% in the extended session on Tuesday.

What Happened: ProPhase said on Tuesday it has acquired mobile app company VaccTrack, which confirms a user has been vaccinated against COVID-19, for an undisclosed amount. 

VaccTrack app awards a digital vaccination certificate, or a “passport," to its users if they have been vaccinated or if they have been tested for the virus and can confirm the test results.

According to ProPhase, the app’s capability could be adopted as a measure that will allow entertainment and sporting venues to safely admit spectators and allow airlines and hotels to safely accept travelers. 

The VaccTrack solution can be accessed on a mobile phone as an app or via a digital wallet.

Why It Matters: More businesses and corporations are planning to return to office as the vaccination rollout picks pace gradually. ProPhase is relying on the corporate and individual need to provide a vaccination safety certificate as more people step out of their homes.

https://www.benzinga.com/general/biotech/21/03/20416240/why-prophase-labs-shares-jumped-32-today